Bionano Genomics (BNGO) EV/EBITDA: History & Chart

Bionano Genomics, Inc.(BNGO)

Medical - Instruments & Supplies · San Diego, CA

$1.46+0.01 (+1.03%)

Delayed quote: Oct 6, 2026, 10:15 AM EDT

About Bionano Genomics, Inc.

Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.

San Diego, CA

96 employees

bionano.com

Healthcare / Medical - Instruments & Supplies

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO: Albert A. Luderer

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Bionano Genomics, Inc. (BNGO)	$16.75M	N/A	N/A	N/A	N/A
Dyadic International, Inc. (DYAI)vs ›	$16.86M	N/A	95.14x	74.72x	74.72x
BioCardia, Inc. (BCDA)vs ›	$16.22M	N/A	30.33x	30.26x	30.26x
Lipocine Inc. (LPCN)vs ›	$17.07M	N/A	19.19x	19.19x	19.19x
Allarity Therapeutics, Inc. (ALLR)vs ›	$15.80M	N/A	N/A	N/A	N/A
Cocrystal Pharma, Inc. (COCP)vs ›	$15.57M	N/A	N/A	N/A	N/A
Marker Therapeutics, Inc. (MRKR)vs ›	$17.76M	N/A	N/A	N/A	N/A
Pasithea Therapeutics Corp. (KTTA)vs ›	$15.27M	N/A	N/A	N/A	N/A
Karyopharm Therapeutics Inc. (KPTI)vs ›	$15.18M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$14.28M	N/A	116.01x	116.01x	116.01x

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Bionano Genomics, Inc. (BNGO)

$16.75M

N/A

Dyadic International, Inc. (DYAI)vs ›

$16.86M

N/A

95.14x

74.72x